Market Access Archives | Page 2 of 7 | Report Store

Commercial Strategy
Hot Topics
Pricing & Reimbursement

Sort by Popularity (sales)

Display 15 Products per page

Psoriasis Pricing, Reimbursement, and Access

$2,995.00

Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.
March 28, 2019
Find out more
Key Trends in European Market Access

$2,995.00

This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.
January 26, 2016
Find out more
Key Potential Drug Launches in 2021

$2,995.00

As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2021.

1.

July 24, 2020
Find out more
Biosimilars in the US and Europe

$2,995.00

Biosimilars have been available in Europe for over a decade, and have offered the opportunity to vastly reduce the cost of treatment for a large number of biologic agents.
June 25, 2019
Find out more
Spotlight on Antibody-Drug Conjugates

$2,995.00

The first antibody-drug conjugate (ADC), Mylotarg, reached the market almost two decades ago. Since this time, the ADC field has undergone slow but transformative enhancements, with improvements to technologies and advancements in the pipeline leading to an invigoration of the field. The past couple of years have seen the approvals of three new ADCs: Polivy, Lumoxiti, and Besponsa, increasing the total number of ADCs approved by regulators worldwide to six. These approvals mark the start of a new era in which the ADC field is finally beginning to realize its full potential. With the ADC pipeline swelling to around 250 novel candidates in various stages of preclinical and clinical development, approvals for more ADCs appear firmly on the horizon.

September 20, 2019
Find out more
2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report

$2,995.00

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications.

June 13, 2019
Find out more
2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report

$2,995.00

The 71st Annual Meeting of the American Academy of Neurology (AAN) was held in Philadelphia, Pennsylvania, from May 4-10, 2019.

May 28, 2019
Find out more
Key Potential Drug Launches in 2020

$2,995.00

As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2020.

May 28, 2019
Find out more
Biosimilar Commercial Strategies and Tactics

$2,995.00

The challenges faced by biosimilar developers are not unlike those confronting their branded counterparts. First, companies must develop high-quality biosimilars and obtain regulatory approval. Next, they must then navigate the vast array of commercial nuances that exist at the national level in order for their products to be used in the clinical setting.
May 14, 2019
Find out more
Access Trends in Emerging Markets

$3,000.00

This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.
February 20, 2019
Find out more
New Pharma Models for a New Healthcare Era

$2,995.00

This analysis includes insights from eight interviewed experts from pharma, medical device, or digital health companies.
December 20, 2018
Find out more
ISPOR Europe 2018 Whitepaper

$2,995.00

Datamonitor Healthcare attended the ISPOR 21st Annual European Congress held in Barcelona on 10–14 November. Here, we present some of the hot topics discussed at the event.

November 23, 2018
Find out more
First-In-Class Therapies’ Shrinking In-Class Monopolies

$2,995.00

Competition from drugs in the same class (with the same mechanism of action and treating the same disease) presents a clear challenge to a first-in-class market entrant. And the speed with which these competitors arrive impacts market dynamics, commercial strategies, and, increasingly, drug prices. Therapies that enjoy extended monopolies as sole entrants in a particular class have greater commercial flexibility in negotiating with payers. Multiple drugs in the same class give payers better leverage with which to negotiate rebates and discounts with drug companies.
November 15, 2018
Find out more
Bladder Cancer Pricing, Reimbursement, and Access

$2,995.00

Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors.
September 27, 2018
Find out more
Value-Based Reimbursement in the US

$2,995.00

The US healthcare environment has been witnessing a slow albeit continuous shift from volume- to value-based reimbursement over the past couple of decades
August 22, 2018
Find out more

Market Access

Psoriasis Pricing, Reimbursement, and Access

Key Trends in European Market Access

Key Potential Drug Launches in 2021

Biosimilars in the US and Europe

Spotlight on Antibody-Drug Conjugates

2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report

2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report

Key Potential Drug Launches in 2020

Biosimilar Commercial Strategies and Tactics

Access Trends in Emerging Markets

New Pharma Models for a New Healthcare Era

ISPOR Europe 2018 Whitepaper

First-In-Class Therapies’ Shrinking In-Class Monopolies

Bladder Cancer Pricing, Reimbursement, and Access

Value-Based Reimbursement in the US